Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a UnitedHealth stock analysis and talk about the risks and upside potential of UNH stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
29 Jul 2025, 17:41 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a UnitedHealth stock analysis and talk about the risks and upside potential of UNH stock
Source overview

AI-generated source summary

The video presents a fundamental analysis of UnitedHealth Group (UNH) following an earnings report that led to a 5% stock price decrease. The company missed earnings per share, reporting $4.08 adjusted versus $4.48 expected, though it beat revenue expectations. A key concern is the rising medical loss ratio, increasing to 89.4% from 85.1% year-over-year, primarily due to faster-rising healthcare expenses than premiums, with a projected $6.5 billion more in medical costs than initially anticipated for 2025. Pricing strategies and exiting some unprofitable markets PPO Medicare are being used as solutions. It is also expected is an 8% return by 2025. Despite the setbacks, the speaker notes that the long-term framework remains intact. It's forward P/E ratio is 16.57, below its average of 18.83 and 13 % is the earnings for long-term growth are set with a target of 600.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail